Literature DB >> 6322829

Systemic absorption of ketoconazole from vaginal pessaries.

M D Ene, P J Williamson, T K Daneshmend, N R Blatchford.   

Abstract

Eight healthy female subjects were each given (a) ketoconazole 400 mg orally, (b) ketoconazole 400 mg as a single vaginal pessary, (c) ketoconazole 800 mg as two vaginal pessaries, and (d) ketoconazole 1200 mg as three vaginal pessaries. The area under the plasma concentration time curve (AUC) after the oral dose was 51.41 +/- 10.99 mg l-1 h (mean +/- s.d.) and the half-life of ketoconazole was 2.98 +/- 1.41 h. The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively. Systemic absorption of single doses of vaginally administered ketoconazole appears to be negligible in the absence of vaginal infection. There were no local or systemic side effects related to ketoconazole in these healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322829      PMCID: PMC1463314          DOI: 10.1111/j.1365-2125.1984.tb02334.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Pharmacokinetics of ketoconazole in normal subjects.

Authors:  T K Daneshmend; D W Warnock; A Turner; C J Roberts
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

Review 2.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  The pharmacokinetics of ketoconazole in severely immunocompromised patients.

Authors:  I M Hann; H G Prentice; M Keaney; R Corringham; H A Blacklock; J Fox; E Gascoigne; J Van Cutsem
Journal:  J Antimicrob Chemother       Date:  1982-12       Impact factor: 5.790

4.  Pharmacokinetics of ketoconazole in patients with neoplastic diseases.

Authors:  A W Maksymiuk; H B Levine; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

5.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

6.  Impairing effect of food on ketoconazole absorption.

Authors:  P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu; P Ottoila
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

7.  Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man.

Authors:  T K Daneshmend; D W Warnock; M D Ene; E M Johnson; G Parker; M D Richardson; C J Roberts
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

  7 in total
  2 in total

1.  Plasma metronidazole concentrations after single and repeated vaginal pessary administration.

Authors:  I G Salas-Herrera; M Lawson; A Johnston; P Turner; D M Gott; M J Dennis
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.